Related Experiment Video
Updated: Jul 3, 2026

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors
Published on: May 9, 2025
Rilpivirine, a non-nucleoside reverse transcriptase inhibitor for the treatment of HIV infection
Diego Ripamonti1, Franco Maggiolo
1Malattie Infettive, Ospedali Riuniti di Bergamo, Largo Barozzi 1, 24128 Bergamo, Italy. diego.ripamonti@hotmail.com
Abstract:
Tibotec BVBA is developing the diarylpyrimidine rilpivirine, a second-generation non-nucleoside reverse transcriptase inhibitor for the potential treatment of HIV infection. A phase III trial of rilpivirine in HIV-infected, treatment-naive indivuduals is underway and is to be completed by August 2010.
Related Concept Videos
Retrovirus Life Cycles
Antiviral Nucleoside Inhibitors
Inhibitors of Virion Maturation and Assembly
Respiratory Syncytial Virus Disease
Inhibitors Of Virion Release
Inhibitors of Viral Protein Synthesis

